Last reviewed · How we verify
TT infant acellular Pertussis
TT infant acellular Pertussis, developed by the London School of Hygiene and Tropical Medicine, is a marketed vaccine for preventing pertussis in infants. The key composition patent expires in 2028, providing a period of exclusivity that supports market stability. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | TT infant acellular Pertussis |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Gambia Pertussis Study (GaPs) (PHASE4)
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (PHASE2)
- Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants (PHASE2)
- Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: